FONR · Fonar Corp
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FONR
this stock
Fonar Corp
|
$13.29M | +2.9% | +1.4% | — | 6.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$214.21B | -0.4% | +0.4% | 31.7 | 1.4% |
|
DHR
Danaher Corp /De/
|
$139.93B | -12.7% | +8.5% | 35.3 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.93B | -15.8% | +10.4% | 41.9 | 2.7% |
|
IQV
Iqvia Holdings Inc.
|
$40.55B | +7.8% | +41.6% | 30.2 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FONR | +0.4% | +1.0% | +34.0% | -0.1% | +2.9% |
| SPY | +0.5% | +4.2% | +10.4% | -0.3% | +10.6% |
| vs SPY | -0.1% | -3.2% | +23.5% | +0.3% | -7.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.